PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions

• Drug: PF-04171327
  
  Oral single 5 mg dose as one 5 mg tablet
• Drug: PF-04171327
  
  Oral single 10 mg dose as one 10 mg tablet
• Drug: PF-04171327
  
  Oral single 30 mg dose as three 10 mg tablets
• Drug: Placebo
  
  Oral single dose as matching placebo
• Drug: PF-04171327
  
  Oral multiple 20 mg doses as two 10 mg tablets for 12 days
• Drug: Placebo
  
  Oral multiple doses as matching placebo for 12 days

• Experimental: Single dose
  
  Interventions:
  

  • Drug: PF-04171327
  • Drug: PF-04171327
  • Drug: PF-04171327
  • Drug: Placebo
• Experimental: Multiple dose
  
  Interventions:
  

  • Drug: PF-04171327
  • Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects of non childbearing potential between the ages of 18 and 55 years.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).
• Japanese subjects who have four Japanese grandparents born in Japan.

Exclusion Criteria:

• Confirmed fasting glucose more than 100 mg/dL at Screening and Day 0 in both Cohort A and B.
• Corticosteroid use of more than 5 mg prednisone equivalent per day for more than 6 weeks.
• Evidence or history of clinically significant hematological (including anemia), renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).